Keep Me Logged In
Eli Lilly stopped the development of its heart drug, evacetrapib, as the treatment was not found effective enough in a late-stage trial, sending its shares down nearly 10 percent in premarket trading.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by